BPMC:NSD-Blueprint Medicines Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 104.21

Change

+0.54 (+0.52)%

Market Cap

USD 6.07B

Volume

0.32M

Avg Analyst Target

USD 117.40 (+12.66%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Blueprint Medicines Corporation has a strategic research collaboration with The University of Texas MD Anderson Cancer Center for accelerating development of BLU-222, an investigational precision therapy that targets cyclin-dependent kinase 2. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 45 Sidney Street, Cambridge, MA, United States, 02139-4133

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.86 (-1.41%)

USD139.56B 40.85 31.63
BNTX BioNTech SE

-13.62 (-4.66%)

USD70.91B 16.26 11.68
REGN Regeneron Pharmaceuticals Inc

-2.55 (-0.43%)

USD62.24B 10.69 7.94
VRTX Vertex Pharmaceuticals Incorpo..

-3.13 (-1.70%)

USD47.75B 24.27 16.15
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-16.37 (-4.27%)

USD35.80B N/A N/A
SGEN Seagen Inc

-3.09 (-1.74%)

USD32.33B 55.44 43.27
GMAB Genmab A/S

-0.46 (-1.01%)

USD30.35B 77.92 9.04
ALNY Alnylam Pharmaceuticals Inc

-6.55 (-3.31%)

USD23.50B N/A N/A
RPRX Royalty Pharma plc

-0.93 (-2.46%)

USD22.91B 30.56 12.22

ETFs Containing BPMC

Symbol Name Weight Mer Price(Change) Market Cap
BBP ETFis Series Trust I - Vi.. 0.00 % 0.79 %

-0.27 (-0.53%)

USD0.03B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

-0.32 (-1.48%)

USD0.25B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

-0.80 (-1.60%)

USD0.33B
AGED:LSE iShares Ageing Population.. 0.00 % 0.40 %

-0.05 (-0.60%)

USD0.98B
AGES:LSE iShares IV Public Limited.. 0.00 % 0.40 %

-3.13 (-0.56%)

USD0.98B
DRDR:LSE iShares IV Public Limited.. 0.00 % 0.40 %

-9.38 (-1.28%)

USD2.34B
HEAL:LSE iShares IV Public Limited.. 0.00 % 0.40 %

-0.11 (-1.12%)

USD2.34B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.08% 63% D 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.08% 63% D 31% F
Trailing 12 Months  
Capital Gain -0.40% 52% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.40% 52% F 24% F
Trailing 5 Years  
Capital Gain 240.11% 80% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 240.11% 80% B- 84% B
Average Annual (5 Year Horizon)  
Capital Gain 32.39% 65% D 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.39% 65% D 76% C
Risk Return Profile  
Volatility (Standard Deviation) 51.30% 62% D- 35% F
Risk Adjusted Return 63.13% 89% B+ 79% C+
Market Capitalization 6.07B 95% A 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.84 33% F 48% F
Price/Book Ratio 4.51 40% F 31% F
Price / Cash Flow Ratio 15.69 5% F 27% F
EV/EBITDA 15.79 24% F 46% F
Management Effectiveness  
Return on Equity 35.62% 97% A+ 94% A
Return on Invested Capital 32.03% 93% A 94% A
Return on Assets 17.74% 98% A+ 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.23 31% F 17% F
Short Percent 4.99% 48% F 34% F
Beta 0.65 81% B- 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.